VWF Antikörper (AA 1815-1939)

Produktnummer ABIN4949942

Dieses Anti-VWF-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von VWF in WB, IP, FACS, IF und IHC (p). Geeignet für Human.

Kurzübersicht für VWF Antikörper (AA 1815-1939) (ABIN4949942)

Target: VWF (Von Willebrand Factor (VWF))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VWF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: VWF-1465

Produktdetails anti-VWF Antikörper

Bindungsspezifität: AA 1815-1939

Aufreinigung: Protein G affinity chromatography

Immunogen: Amino acids 1815-1939 from the human protein were used as the immunogen for this vWF antibody.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: The optimal dilution of the vWF antibody for each application should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT,WB: 0.5-1 μg/mL,IP: 1-2 μg/500 μg lysate

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu VWF

Target: VWF (Von Willebrand Factor (VWF))

Andere Bezeichnung: von Willebrand Factor / vWF

Hintergrund: Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.